(CTN News) – The deadly disease of myeloma, a form of blood cancer that is relentless in its pathology, may be affecting you or a loved one right now.
Think about the possibility of a breakthrough that promises a new chance and a chance at a fuller life in the future. I am delighted to share with you today the latest development in the treatment of multiple myeloma – a “game-changing” triple therapy has been approved for use in treating this disease.
In the UK, around 6,000 people are diagnosed with myeloma each year. The disease can be debilitating, causing fatigue, pain in the bones, and other symptoms.
In the past, high-dose chemotherapy and stem cell transplants were the most common treatments available for patients suffering from this disease.
Nevertheless, they are not suitable for all patients, which leaves two-thirds of them in a difficult position in the long run. It is precisely here that the revolutionary triple therapy, known as DRD (daratumumab, lenalidomide, and dexamethasone), comes into play.
An exciting triple therapy known as DRD, which is being promoted by the National Institute for Health and Care Excellence (NICE), has been given the green light. In the event that you are not able to undergo a stem cell transplant, this treatment could be a game-changer for you.
There is more time to spend with your loved ones when you choose triple Myeloma therapy
As a result of the clinical data presented to the health authorities, astounding results were revealed. As compared to the previous standard of lenalidomide plus dexamethasone, DRD reduces the risk of disease progression and death by a staggering 45% compared to the older standard of lenalidomide alone.
You may be able to enjoy more precious years with this treatment due to the fact that you will typically be able to live without the disease progressing for up to five years compared to less than three years with the previous treatment.
In addition to reducing the risk of death by 34%, the combination drugs are also bringing hope on another front. It is important to realize that this breakthrough is not just about statistics. It is about the ability to create more moments with your loved ones, to live a fuller life, and to create more moments with your family.
It is a lifeline for thousands of people
Approximately 4,000 myeloma patients could benefit each year from this life-changing combination of drugs, according to Myeloma UK, a leading charity in the field.
This represents a significant leap forward in myeloma treatment in a world where only half of myeloma patients survive for five years or more, and just a third live to be a decade old.